food and drug administration has allowed icn pharmaceuticals inc resume testing its ribavirin experimental aids drug according icn safety concerns not sufficient magnitude withhold approval further clinical studies designed assess safety and efficacy ribavirin fda told icn chairman milan panic october letter made public icn fda spokesman confirmed authenticity letter icn tests drug humans were blocked last spring after fda decided was insufficient evidence its effectiveness against two common aids related conditions tests had been intended determine whether ribavirin was effective against aids related complex arc and lymphadenopathy syndrome fda commissioner frank young disclosed may however agency was investigating suspicious test results submitted icn antiviral drug young said had personally scolded icn officials for making exaggerated claims about drug addition house subcommittee said was probing icn for possible trading financial irregularities today fda said was letting icn test ribavirin for safety and effectiveness patients with arc and reuter 